Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 219

1.

Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial.

Fan KR, Baskaran M, Nongpiur ME, Htoon HM, de Leon JMS, Perera SA, Belkin M, Aung T.

Acta Ophthalmol. 2019 Sep;97(6):e827-e832. doi: 10.1111/aos.14099. Epub 2019 Mar 27.

PMID:
30916898
2.

Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study.

Zecca C, Pavelek Z, Přikrylová K, Ghielmetti M, Beeler A, Gobbi C.

Mult Scler Relat Disord. 2019 May;30:104-109. doi: 10.1016/j.msard.2019.02.010. Epub 2019 Feb 6.

PMID:
30763907
3.

Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.

Cascione M, Tenenbaum N, Wendt J, Meng X, Schofield L, Cree BAC; PREFERMS investigators.

Mult Scler Relat Disord. 2018 Oct;25:50-56. doi: 10.1016/j.msard.2018.07.014. Epub 2018 Jul 11.

4.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

5.

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.

Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.

Clin Ther. 2017 Aug;39(8):1671-1679. doi: 10.1016/j.clinthera.2017.06.012. Epub 2017 Jul 25.

6.

Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.

Ozakbas S, Cinar BP, Kosehasanoğullari G, Kahraman T, Oz D, Kursun BB.

Clin Neurol Neurosurg. 2017 Sep;160:69-72. doi: 10.1016/j.clineuro.2017.06.016. Epub 2017 Jun 27.

PMID:
28689102
7.

Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison.

Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR.

J Comp Eff Res. 2017 Jun;6(4):313-323. doi: 10.2217/cer-2016-0085. Epub 2017 Mar 28.

8.

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.

Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL.

Eur J Neurol. 2017 May;24(5):726-733. doi: 10.1111/ene.13272. Epub 2017 Mar 22.

9.

A Potential Life-Threatening Reaction to Glatiramer Acetate in Rett Syndrome.

Nissenkorn A, Kidon M, Ben-Zeev B.

Pediatr Neurol. 2017 Mar;68:40-43. doi: 10.1016/j.pediatrneurol.2016.11.006. Epub 2016 Dec 7.

PMID:
28254244
10.

[Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].

Boyko AN, Lashch NY, Sharanova SN, Zakharova MN, Trifonova OV, Simaniv TO, Lysogorskaya EV, Guryanova OE, Kotov SV, Iakushina TI, Lizhdvoy VY, Belova YA, Khabirov FA, Babicheva NN, Khaibullin TI, Granatov EV, Averyanova LA, Sazonov DV, Odinak MM, Trinitatsky YV, Tsukurova LA, Sergeeva AI, Ivanov RA, Shustova MS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10 Pt 2):61-67. doi: 10.17116/jnevro201611610261-67. Russian.

PMID:
28139613
11.

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.

Selmaj K, Barkhof F, Belova AN, Wolf C, van den Tweel ER, Oberyé JJ, Mulder R, Egging DF, Koper NP, Cohen JA; GATE study group.

Mult Scler. 2017 Dec;23(14):1909-1917. doi: 10.1177/1352458516688956. Epub 2017 Jan 16.

12.

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.

Schwartzbach CJ, Grove RA, Brown R, Tompson D, Then Bergh F, Arnold DL.

J Neurol. 2017 Feb;264(2):304-315. doi: 10.1007/s00415-016-8341-7. Epub 2016 Nov 25.

13.

Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.

Cinar BP, Kösehasanoğulları G, Yigit P, Ozakbas S.

Neurol Sci. 2017 Feb;38(2):337-342. doi: 10.1007/s10072-016-2775-7. Epub 2016 Nov 24.

PMID:
27885448
14.

Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.

Wang G, Cutter GR, Cofield SS, Lublin F, Wolinsky JS, Gustafson T, Krieger S, Salter A.

Mult Scler. 2017 Jun;23(7):982-987. doi: 10.1177/1352458516670733. Epub 2016 Sep 28.

15.

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.

Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R.

Mult Scler. 2017 May;23(6):818-829. doi: 10.1177/1352458516664033. Epub 2016 Aug 8.

PMID:
27503905
16.

MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.

Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DL.

Neurology. 2016 Aug 30;87(9):905-11. doi: 10.1212/WNL.0000000000003043. Epub 2016 Jul 29.

17.

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Derfuss T, Ontaneda D, Nicholas J, Meng X, Hawker K.

Mult Scler Relat Disord. 2016 Jul;8:124-30. doi: 10.1016/j.msard.2016.05.015. Epub 2016 May 24.

18.

Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate.

Djukic A, Holtzer R, Shinnar S, Muzumdar H, Rose SA, Mowrey W, Galanopoulou AS, Shinnar R, Jankowski JJ, Feldman JF, Pillai S, Moshé SL.

Pediatr Neurol. 2016 Aug;61:51-7. doi: 10.1016/j.pediatrneurol.2016.05.010. Epub 2016 May 27.

PMID:
27363291
19.

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.

de Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundström P, Svenningsson A.

Neurology. 2016 Jul 12;87(2):141-7. doi: 10.1212/WNL.0000000000002832. Epub 2016 Jun 17.

PMID:
27316241
20.

Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis.

MacKenzie-Graham A, Kurth F, Itoh Y, Wang HJ, Montag MJ, Elashoff R, Voskuhl RR.

JAMA Neurol. 2016 Aug 1;73(8):944-53. doi: 10.1001/jamaneurol.2016.0966.

Supplemental Content

Loading ...
Support Center